EDN1 and cancer: Losartan, the angiotensin II receptor blocker, inactivates cancer-associated fibroblasts (CAFs), decreases stromal collagen and hyaluronan production, and reduces TGFβ1, connective tissue growth factor (CCN2, cellular communication network factor 2), and endothelin-1 (ET-1), thereby lowering mechanical compression in tumors and increasing vascular perfusion [104].